The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function

Vascular Pharmacology

Volumn 55, Issue 1-3, 2011, Pages 17-25

  Meyer, Matthias R ^a,b   Prossnitz, Eric R ^b   Barton, Matthias ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Blood pressure; Endothelium; Menopause; Nitric oxide; Vasodilation

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; G 1; G 15; G PROTEIN COUPLED RECEPTOR 30; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; BREAST CANCER; CARDIOVASCULAR FUNCTION; CORONARY ARTERY DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; HYPERTENSION; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VASODILATATION;

ANIMALS; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CARDIOVASCULAR SYSTEM; HUMANS; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED;

EID: 80051781308     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2011.06.003     Document Type: Review

References (124)

1. Abdelhamid R., Luo J., VandeVrede L., Kundu I., Michalsen B., Litosh V.A., Schiefer I.T., Gherezghiher T., Yao P., Qin Z., Thatcher G.R.J. Benzothiophene selective estrogen receptor modulators provide neuroprotection by a novel GPR30-dependent mechanism. ACS Chem. Neurosci. 2011, 18:256-268.
2. Al Zubair K., Razak A., Bexis S., Docherty J.R. Relaxations to oestrogen receptor subtype selective agonists in rat and mouse arteries. Eur. J. Pharmacol. 2005, 513:101-108.
3. Albanito L., Madeo A., Lappano R., Vivacqua A., Rago V., Carpino A., Oprea T.I., Prossnitz E.R., Musti A.M., Ando S., Maggiolini M. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 2007, 67:1859-1866.
4. Alexander S.P., Mathie A., Peters J.A. Guide to Receptors and Channels (GRAC), 3rd edition. Br. J. Pharmacol. 2008, 153(Suppl 2):S1-S209.
5. Babiker F.A., Lips D.J., Delvaux E., Zandberg P., Janssen B.J., Prinzen F., van Eys G., Grohe C., Doevendans P.A. Oestrogen modulates cardiac ischaemic remodelling through oestrogen receptor-specific mechanisms. Acta Physiol. (Oxf). 2007, 189:23-31.
6. Barrett-Connor E., Mosca L., Collins P., Geiger M.J., Grady D., Kornitzer M., McNabb M.A., Wenger N.K. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 2006, 355:125-137.
7. Barton M., Meyer M.R. Postmenopausal hypertension: mechanisms and therapy. Hypertension 2009, 54:11-18.
8. Barton M., Cremer J., Mügge A. 17beta-estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries. Eur. J. Pharmacol. 1998, 362:73-76.
9. Bolego C., Cignarella A., Sanvito P., Pelosi V., Pellegatta F., Puglisi L., Pinna C. The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-alpha agonists and is abolished by estrogen deprivation. J. Pharmacol. Exp. Ther. 2005, 313:1203-1208.
10. Bologa C.G., Revankar C.M., Young S.M., Edwards B.S., Arterburn J.B., Kiselyov A.S., Parker M.A., Tkachenko S.E., Savchuck N.P., Sklar L.A., Oprea T.I., Prossnitz E.R. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol. 2006, 2:207-212.
11. Bopassa J.C., Eghbali M., Toro L., Stefani E. A novel estrogen receptor GPER inhibits mitochondria permeability transition pore opening and protects the heart against ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H16-H23.
12. Bracamonte M.P., Jayachandran M., Rud K.S., Miller V.M. Acute effects of 17beta-estradiol on femoral veins from adult gonadally intact and ovariectomized female pigs. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H2389-H2396.
13. Broughton B.R., Miller A.A., Sobey C.G. Endothelium-dependent relaxation by G protein-coupled receptor 30 agonists in rat carotid arteries. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H1055-H1061.
14. Burger N.Z., Kuzina O.Y., Osol G., Gokina N.I. Estrogen replacement enhances EDHF-mediated vasodilation of mesenteric and uterine resistance arteries: role of endothelial cell Ca2+. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E503-E512.
15. Burt V.L., Whelton P., Roccella E.J., Brown C., Cutler J.A., Higgins M., Horan M.J., Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995, 25:305-313.
16. Cagnacci A., Zanni A.L., Volpe A. Administration of raloxifene does not influence 24-hour ambulatory blood pressure of postmenopausal women with osteopenia: a double-blind placebo-controlled study. Am. J. Obstet. Gynecol. 2003, 188:1278-1282.
17. Chambliss K.L., Yuhanna I.S., Mineo C., Liu P., German Z., Sherman T.S., Mendelsohn M.E., Anderson R.G., Shaul P.W. Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ. Res. 2000, 87:E44-E52.
18. Chambliss K.L., Yuhanna I.S., Anderson R.G., Mendelsohn M.E., Shaul P.W. ERbeta has nongenomic action in caveolae. Mol. Endocrinol. 2002, 16:938-946.
19. Chambliss K.L., Wu Q., Oltmann S., Konaniah E.S., Umetani M., Korach K.S., Thomas G.D., Mineo C., Yuhanna I.S., Kim S.H., Madak-Erdogan Z., Maggi A., Dineen S.P., Roland C.L., Hui D.Y., Brekken R.A., Katzenellenbogen J.A., Katzenellenbogen B.S., Shaul P.W. Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J. Clin. Invest. 2010, 120:2319-2330.
20. Chan Y.C., Leung F.P., Wong W.T., Tian X.Y., Yung L.M., Lau C.W., Tsang S.Y., Yao X., Chen Z.Y., Huang Y. Therapeutically relevant concentrations of raloxifene dilate pressurized rat resistance arteries via calcium-dependent endothelial nitric oxide synthase activation. Arterioscler. Thromb. Vasc. Biol. 2010, 30:992-999.
21. Chow R.W., Handelsman D.J., Ng M.K. Minireview: rapid actions of sex steroids in the endothelium. Endocrinology 2010, 151:2411-2422.
22. Chung M.T., Cheng P.Y., Lam K.K., Chen S.Y., Ting Y.F., Yen M.H., Lee Y.M. Cardioprotective effects of long-term treatment with raloxifene, a selective estrogen receptor modulator, on myocardial ischemia/reperfusion injury in ovariectomized rats. Menopause 2010, 17:127-134.
23. Collins P., Mosca L., Geiger M.J., Grady D., Kornitzer M., Amewou-Atisso M.G., Effron M.B., Dowsett S.A., Barrett-Connor E., Wenger N.K. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 2009, 119:922-930.
24. Cruz M.N., Douglas G., Gustafsson J.A., Poston L., Kublickiene K. Dilatory responses to estrogenic compounds in small femoral arteries of male and female estrogen receptor-beta knockout mice. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H823-H829.
25. Cummings S.R., Ensrud K., Delmas P.D., LaCroix A.Z., Vukicevic S., Reid D.M., Goldstein S., Sriram U., Lee A., Thompson J., Armstrong R.A., Thompson D.D., Powles T., Zanchetta J., Kendler D., Neven P., Eastell R. Lasofoxifene in postmenopausal women with osteoporosis. N. Engl. J. Med. 2010, 362:686-696.
26. Darblade B., Pendaries C., Krust A., Dupont S., Fouque M.J., Rami J., Chambon P., Bayard F., Arnal J.F. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ. Res. 2002, 90:413-419.
27. Darkow D.J., Lu L., White R.E. Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. Am. J. Physiol. 1997, 272:H2765-H2773.
28. Das B., Sarkar C. Similarities between ischemic preconditioning and 17beta-estradiol mediated cardiomyocyte KATP channel activation leading to cardioprotective and antiarrhythmic effects during ischemia/reperfusion in the intact rabbit heart. J. Cardiovasc. Pharmacol. 2006, 47:277-286.
29. Delbeck M., Golz S., Vonk R., Janssen W., Hucho T., Isensee J., Schäfer S., Otto C. Impaired left-ventricular cardiac function in male GPR30-deficient mice. Mol. Med. Rep. 2011, 4:37-40.
30. Delyani J.A., Murohara T., Nossuli T.O., Lefer A.M. Protection from myocardial reperfusion injury by acute administration of 17 beta-estradiol. J. Mol. Cell. Cardiol. 1996, 28:1001-1008.
31. Dennis M.K., Burai R., Ramesh C., Petrie W.K., Alcon S.N., Nayak T.K., Bologa C.G., Leitao A., Brailoiu E., Deliu E., Dun N.J., Sklar L.A., Hathaway H.J., Arterburn J.B., Oprea T.I., Prossnitz E.R. In vivo effects of a GPR30 antagonist. Nat. Chem. Biol. 2009, 5:421-427.
32. Deschamps A.M., Murphy E. Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H1806-H1813.
33. Deschamps A.M., Murphy E., Sun J. Estrogen receptor activation and cardioprotection in ischemia reperfusion injury. Trends Cardiovasc. Med. 2010, 20:73-78.
34. Ding Q., Gros R., Limbird L.E., Chorazyczewski J., Feldman R.D. Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR30. Am. J. Physiol. Cell. Physiol. 2009, 297:C1178-C1187.
35. Ensrud K., LaCroix A., Thompson J.R., Thompson D.D., Eastell R., Reid D.M., Vukicevic S., Cauley J., Barrett-Connor E., Armstrong R., Welty F., Cummings S. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation 2010, 122:1716-1724.
36. Figtree G.A., Lu Y., Webb C.M., Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 1999, 100:1095-1101.
37. Filardo E.J., Quinn J.A., Bland K.I., Frackelton A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 2000, 14:1649-1660.
38. Filice E., Recchia A.G., Pellegrino D., Angelone T., Maggiolini M., Cerra M.C. A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat. J. Physiol. Pharmacol. 2009, 60:3-10.
39. Furchgott R.F. Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that acid-activable inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. Vasodilation: Vascular Smooth Muscle, Peptides, Autonomic Nerves and Endothelium 1988, 401-414. Raven Press, New York. P.M. Vanhoutte (Ed.).
40. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
41. Gao F., Ma X., Ostmann A.B., Das S.K. GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERalpha) phosphorylation signals. Endocrinology 2011, 152:1434-1447.
42. Gisclard V., Miller V.M., Vanhoutte P.M. Effect of 17 beta-estradiol on endothelium-dependent responses in the rabbit. J. Pharmacol. Exp. Ther. 1988, 244:19-22.
43. Gros R., Ding Q., Sklar L.A., Prossnitz E.R., Arterburn J.B., Chorazyczewski J., Feldman R.D. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 2011, 57:442-451.
44. Guo X., Razandi M., Pedram A., Kassab G., Levin E.R. Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors alpha and beta. J. Biol. Chem. 2005, 280:19704-19710.
45. Haas E., Meyer M.R., Schurr U., Bhattacharya I., Minotti R., Nguyen H.H., Heigl A., Lachat M., Genoni M., Barton M. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 2007, 49:1358-1363.
46. Haas E., Bhattacharya I., Brailoiu E., Damjanovic M., Brailoiu G.C., Gao X., Mueller-Guerre L., Marjon N.A., Gut A., Minotti R., Meyer M.R., Amann K., Ammann E., Perez-Dominguez A., Genoni M., Clegg D.J., Dun N.J., Resta T.C., Prossnitz E.R., Barton M. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ. Res. 2009, 104:288-291.
47. Hale S.L., Birnbaum Y., Kloner R.A. Beta-estradiol, but not alpha-estradiol, reduced myocardial necrosis in rabbits after ischemia and reperfusion. Am. Heart J. 1996, 132:258-262.
48. Hale S.L., Birnbaum Y., Kloner R.A. Estradiol, administered acutely, protects ischemic myocardium in both female and male rabbits. J. Cardiovasc. Pharmacol. Ther. 1997, 2:47-52.
49. Han G., Ma H., Chintala R., Miyake K., Fulton D.J., Barman S.A., White R.E. Nongenomic, endothelium-independent effects of estrogen on human coronary smooth muscle are mediated by type I (neuronal) NOS and PI3-kinase-Akt signaling. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H314-H321.
50. Han G., Barman S.A., White R.E. Rapid estrogen signaling via GPR30 in coronary artery smooth muscle. FASEB J. 2009, 23(Meeting Abstract Supplement). abstract 968.5.
51. Han G., Ma H., Barman S.A., Sellers M., Yu X., Stallone J.N., White R.E. Rapid estrogen signaling via GPER in human coronary artery smooth muscle. FASEB J. 2010, 24(Meeting Abstract Supplement). abstract 957.1.
52. Harada N., Sasano H., Murakami H., Ohkuma T., Nagura H., Takagi Y. Localized expression of aromatase in human vascular tissues. Circ. Res. 1999, 84:1285-1291.
53. Harrington W.R., Sheng S., Barnett D.H., Petz L.N., Katzenellenbogen J.A., Katzenellenbogen B.S. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol. Cell. Endocrinol. 2003, 206:13-22.
54. Haynes M.P., Sinha D., Russell K.S., Collinge M., Fulton D., Morales-Ruiz M., Sessa W.C., Bender J.R. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ. Res. 2000, 87:677-682.
55. Hsieh Y.C., Yu H.P., Frink M., Suzuki T., Choudhry M.A., Schwacha M.G., Chaudry I.H. G protein-coupled receptor 30-dependent protein kinase A pathway is critical in nongenomic effects of estrogen in attenuating liver injury after trauma-hemorrhage. Am. J. Pathol. 2007, 170:1210-1218.
56. Hsieh C.Y., Miaw C.L., Hsieh C.C., Tseng H.C., Yang Y.H., Yen C.H. Effects of chronic 4-n-nonylphenol treatment on aortic vasoconstriction and vasorelaxation in rats. Arch. Toxicol. 2009, 83:941-946.
57. Huang A., Sun D., Wu Z., Yan C., Carroll M.A., Jiang H., Falck J.R., Kaley G. Estrogen elicits cytochrome P450-mediated flow-induced dilation of arterioles in NO deficiency: role of PI3K-Akt phosphorylation in genomic regulation. Circ. Res. 2004, 94:245-252.
58. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA 1998, 280:605-613.
59. Hutchison S.J., Chou T.M., Chatterjee K., Sudhir K. Tamoxifen is an acute, estrogen-like, coronary vasodilator of porcine coronary arteries in vitro. J. Cardiovasc. Pharmacol. 2001, 38:657-665.
60. Ignarro L.J., Buga G.M., Wood K.S., Byrns R.E., Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:9265-9269.
61. Isensee J., Meoli L., Zazzu V., Nabzdyk C., Witt H., Soewarto D., Effertz K., Fuchs H., Gailus-Durner V., Busch D., Adler T., de Angelis M.H., Irgang M., Otto C., Noppinger P.R. Expression pattern of G protein-coupled receptor 30 in LacZ reporter mice. Endocrinology 2009, 150:1722-1730.
62. Jacobs M.N., Lewis D.F. Steroid hormone receptors and dietary ligands: a selected review. Proc. Nutr. Soc. 2002, 61:105-122.
63. Jessup J.A., Lindsey S.H., Wang H., Chappell M.C., Groban L. Attenuation of salt-induced cardiac remodeling and diastolic dysfunction by the GPER agonist G-1 in female mRen2.Lewis rats. PLoS One 2010, 5. published online.
64. Jones S.P., Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J. Mol. Cell. Cardiol. 2006, 40:16-23.
65. Katzenellenbogen B.S., Katzenellenbogen J.A. Defining the "S" in SERMs. Science 2002, 295:2380-2381.
66. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
67. Keung W., Chan M.L., Ho E.Y., Vanhoutte P.M., Man R.Y. Non-genomic activation of adenylyl cyclase and protein kinase G by 17beta-estradiol in vascular smooth muscle of the rat superior mesenteric artery. Pharmacol. Res. 2011, published online.
68. Knock G.A., Mahn K., Mann G.E., Ward J.P., Aaronson P.I. Dietary soy modulates endothelium-dependent relaxation in aged male rats: increased agonist-induced endothelium-derived hyperpolarising factor and basal nitric oxide activity. Free Radic. Biol. Med. 2006, 41:731-739.
69. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:5925-5930.
70. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., van der Burg B., Gustafsson J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139:4252-4263.
71. Leung H.S., Yung L.M., Leung F.P., Yao X., Chen Z.Y., Ko W.H., Laher I., Huang Y. Tamoxifen dilates porcine coronary arteries: roles for nitric oxide and ouabain-sensitive mechanisms. Br. J. Pharmacol. 2006, 149:703-711.
72. Leung F.P., Yung L.M., Leung H.S., Au C.L., Yao X., Vanhoutte P.M., Laher I., Huang Y. Therapeutic concentrations of raloxifene augment nitric oxide-dependent coronary artery dilatation in vitro. Br. J. Pharmacol. 2007, 152:223-229.
73. Leung H.S., Seto S.W., Kwan Y.W., Leung F.P., Au A.L., Yung L.M., Yao X., Huang Y. Endothelium-independent relaxation to raloxifene in porcine coronary artery. Eur. J. Pharmacol. 2007, 555:178-184.
74. Lin J., Steenbergen C., Murphy E., Sun J. Estrogen receptor-beta activation results in S-nitrosylation of proteins involved in cardioprotection. Circulation 2009, 120:245-254.
75. Lindsey S.H., Cohen J.A., Brosnihan K.B., Gallagher P.E., Chappell M.C. Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology 2009, 150:3753-3758.
76. Lindsey S.H., Carver K.A., Prossnitz E.R., Chappell M.C. Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2.Lewis female rat. J. Cardiovasc. Pharmacol. 2011, 57:598-603.
77. Ludmer P.L., Selwyn A.P., Shook T.L., Wayne R.R., Mudge G.H., Alexander R.W., Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 1986, 315:1046-1051.
78. Luksha L., Poston L., Gustafsson J.A., Hultenby K., Kublickiene K. The oestrogen receptor beta contributes to sex related differences in endothelial function of murine small arteries via EDHF. J. Physiol. 2006, 577:945-955.
79. Ma Y., Qiao X., Falone A.E., Reslan O.M., Sheppard S.J., Khalil R.A. Gender-specific reduction in contraction is associated with increased estrogen receptor expression in single vascular smooth muscle cells of female rat. Cell. Physiol. Biochem. 2010, 26:457-470.
80. Martensson U.E., Salehi S.A., Windahl S., Gomez M.F., Sward K., Daszkiewicz-Nilsson J., Wendt A., Andersson N., Hellstrand P., Grande P.O., Owman C., Rosen C.J., Adamo M.L., Lundquist I., Rorsman P., Nilsson B.O., Ohlsson C., Olde B., Leeb-Lundberg L.M. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 2009, 150:687-698.
81. Martin D., Song J., Mark C., Eyster K. Understanding the cardiovascular actions of soy isoflavones: potential novel targets for antihypertensive drug development. Cardiovasc. Hematol. Disord. Drug Targets 2008, 8:297-312.
82. Matthews J., Gustafsson J.A. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol. Interv. 2003, 3:281-292.
83. Mercier I., Mader S., Calderone A. Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism. Cardiovasc. Res. 2003, 59:883-892.
84. Meyer M.R., Barton M. ERalpha, ERbeta, and gpER: novel aspects of oestrogen receptor signalling in atherosclerosis. Cardiovasc. Res. 2009, 83:605-610.
85. Meyer M.R., Haas E., Barton M. Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension 2006, 47:1019-1026.
86. Meyer M.R., Haas E., Prossnitz E.R., Barton M. Non-genomic regulation of vascular cell function and growth by estrogen. Mol. Cell. Endocrinol. 2009, 308:9-16.
87. Meyer M.R., Baretella O., Prossnitz E.R., Barton M. Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780. Pharmacology 2010, 86:58-64.
88. Miller V.M., Duckles S.P. Vascular actions of estrogens: functional implications. Pharmacol. Rev. 2008, 60:210-241.
89. Morgante G., Delia A., Musacchio M.C., Severi F.M., Petraglia F., De Leo V. Effects of raloxifene therapy on plasma renin and aldosterone levels and blood pressure in postmenopausal women. Gynecol. Endocrinol. 2006, 22:376-380.
90. Mügge A., Riedel M., Barton M., Kuhn M., Lichtlen P.R. Endothelium independent relaxation of human coronary arteries by 17 beta-oestradiol in vitro. Cardiovasc. Res. 1993, 27:1939-1942.
91. Mügge A., Barton M., Fieguth H.G., Riedel M. Contractile responses to histamine, serotonin, and angiotensin II are impaired by 17 beta-estradiol in human internal mammary arteries in vitro. Pharmacology 1997, 54:162-168.
92. Nemcsik J., Morschl E., Egresits J., Kordas K., Laszlo F., Laszlo F.A., Pavo I. Raloxifene lowers ischaemia susceptibility by increasing nitric oxide generation in the heart of ovariectomized rats in vivo. Eur. J. Pharmacol. 2004, 495:179-184.
93. Ogita H., Node K., Asanuma H., Sanada S., Liao Y., Takashima S., Asakura M., Mori H., Shinozaki Y., Hori M., Kitakaze M. Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. J. Am. Coll. Cardiol. 2002, 40:998-1005.
94. Ogita H., Node K., Asanuma H., Sanada S., Kim J., Takashima S., Minamino T., Hori M., Kitakaze M. Raloxifene improves coronary perfusion, cardiac contractility, and myocardial metabolism in the ischemic heart: role of phosphatidylinositol 3-kinase/Akt pathway. J. Cardiovasc. Pharmacol. 2004, 43:821-829.
95. Patel V.H., Chen J., Ramanjaneya M., Karteris E., Zachariades E., Thomas P., Been M., Randeva H.S. G-protein coupled estrogen receptor 1 expression in rat and human heart: protective role during ischaemic stress. Int. J. Mol. Med. 2010, 26:193-199.
96. Prossnitz E.R., Barton M. Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. Prostaglandins Other Lipid Mediat. 2009, 89:89-97.
97. Recchia A.G., De Francesco E.M., Vivacqua A., Sisci D., Panno M.L., Ando S., Maggiolini M. The G protein-coupled receptor 30 is up-regulated by hypoxia inducible factor-1{alpha} (HIF-1{alpha}) in breast cancer cells and cardiomyocytes. J. Biol. Chem. 2011, 286:10773-10782.
98. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307:1625-1630.
99. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
100. Ruehlmann D.O., Steinert J.R., Valverde M.A., Jacob R., Mann G.E. Environmental estrogenic pollutants induce acute vascular relaxation by inhibiting L-type Ca2+ channels in smooth muscle cells. FASEB J. 1998, 12:613-619.
101. Scott P.A., Tremblay A., Brochu M., St-Louis J. Vasorelaxant action of 17-estradiol in rat uterine arteries: role of nitric oxide synthases and estrogen receptors. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H3713-H3719.
102. Shanle E.K., Xu W. Selectively targeting estrogen receptors for cancer treatment. Adv. Drug Deliv. Rev. 2010, 62:1265-1276.
103. Shaw L., Taggart M.J., Austin C. Mechanisms of 17 beta-oestradiol induced vasodilatation in isolated pressurized rat small arteries. Br. J. Pharmacol. 2000, 129:555-565.
104. Silva de Sa M.F., Meirelles R.S. Vasodilating effect of estrogen on the human umbilical artery. Gynecol. Invest. 1977, 8:307-313.
105. Simoncini T., Hafezi-Moghadam A., Brazil D.P., Ley K., Chin W.W., Liao J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000, 407:538-541.
106. Simoncini T., Genazzani A.R., Liao J.K. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 2002, 105:1368-1373.
107. Soloff M.S., Szego C.M. Purification of estradiol receptor from rat uterus and blockade of its estrogen-binding function by specific antibody. Biochem. Biophys. Res. Commun. 1969, 34:141-147.
108. Sudhir K., Chou T.M., Mullen W.L., Hausmann D., Collins P., Yock P.G., Chatterjee K. Mechanisms of estrogen-induced vasodilation: in vivo studies in canine coronary conductance and resistance arteries. J. Am. Coll. Cardiol. 1995, 26:807-814.
109. Sumino H., Ichikawa S., Kasama S., Takahashi T., Kumakura H., Takayama Y., Kanda T., Murakami M., Kurabayashi M. Effects of raloxifene on the renin-angiotensin-aldosterone system and blood pressure in hypertensive and normotensive osteoporotic postmenopausal women. Geriatr. Gerontol. Int. 2010, 10:70-77.
110. Takada Y., Kato C., Kondo S., Korenaga R., Ando J. Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem. Biophys. Res. Commun. 1997, 240:737-741.
111. Teoh H., Leung S.W., Man R.Y. Short-term exposure to physiological levels of 17 beta-estradiol enhances endothelium-independent relaxation in porcine coronary artery. Cardiovasc. Res. 1999, 42:224-231.
112. Thomas P., Dong J. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J. Steroid. Biochem. Mol. Biol. 2006, 102:175-179.
113. Thomas P., Pang Y., Filardo E.J., Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005, 146:624-632.
114. Traupe T., Stettler C.D., Li H., Haas E., Bhattacharya I., Minotti R., Barton M. Distinct roles of estrogen receptors alpha and beta mediating acute vasodilation of epicardial coronary arteries. Hypertension 2007, 49:1364-1370.
115. Ullrich N.D., Krust A., Collins P., MacLeod K.T. Genomic deletion of estrogen receptors ERalpha and ERbeta does not alter estrogen-mediated inhibition of Ca2+ influx and contraction in murine cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H2421-H2427.
116. Umetani M., Domoto H., Gormley A.K., Yuhanna I.S., Cummins C.L., Javitt N.B., Korach K.S., Shaul P.W., Mangelsdorf D.J. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 2007, 13:1185-1192.
117. Ushio-Fukai M. Vascular signaling through G protein-coupled receptors: new concepts. Curr. Opin. Nephrol. Hypertens. 2009, 18:153-159.
118. Vasan R.S., Larson M.G., Leip E.P., Evans J.C., O'Donnell C.J., Kannel W.B., Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N. Engl. J. Med. 2001, 345:1291-1297.
119. Vergote I., Abram P. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Ann. Oncol. 2006, 17:200-204.
120. Weil B.R., Manukyan M.C., Herrmann J.L., Wang Y., Abarbanell A.M., Poynter J.A., Meldrum D.R. Signaling via GPR30 protects the myocardium from ischemia/reperfusion injury. Surgery 2010, 148:436-443.
121. White R.E. Estrogen and vascular function. Vascul. Pharmacol. 2002, 38:73-80.
122. White R.E., Darkow D.J., Lang J.L. Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ. Res. 1995, 77:936-942.
123. Zhang B., Subramanian S., Dziennis S., Jia J., Uchida M., Akiyoshi K., Migliati E., Lewis A.D., Vandenbark A.A., Offner H., Hurn P.D. Estradiol and G1 reduce infarct size and improve immunosuppression after experimental stroke. J. Immunol. 2010, 184:4087-4094.
124. Zhu Y., Bian Z., Lu P., Karas R.H., Bao L., Cox D., Hodgin J., Shaul P.W., Thoren P., Smithies O., Gustafsson J.A., Mendelsohn M.E. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 2002, 295:505-508.